Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Yahoo Finance • 3 days ago

39 New Companies Join the 2026 Fortune Best Companies to Work For Southeast Asia List

Nearly two in five companies on this year's list are first-time entrants. DHL Group stays at No. 1. SINGAPORE, Nov. 3, 2026 /PRNewswire/ -- Fortune and Great Place To Work today named the 2026 Fortune Best Companies to Work For Southeast... Full story

Yahoo Finance • 7 days ago

Takeda H1 profit rises on cost savings, currency gains; hikes FY outlook

Investing.com-- Takeda Pharmaceutical Co., Ltd. (TYO:4502) reported a stronger operating profit for the first half on Thursday, aided by increased cost-cutting measures and sustained weakness in the yen, which boosted returns from overseas... Full story

Yahoo Finance • 7 days ago

Takeda Pharmaceutical Non-GAAP EPS of ¥308.00, revenue of ¥2407B; upgrades FY 2026 outlook

* Takeda Pharmaceutical press release [https://seekingalpha.com/pr/20704779-takeda-announces-fy2026-first-half-results-highlighting-launch-momentum-and-pipeline] (TAK [https://seekingalpha.com/symbol/TAK]): 1H Non-GAAP EPS of ¥308.00.... Full story

Yahoo Finance • 13 days ago

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026 Arcotatug Tavatecan Met Dual Primary Endpo... Full story

Yahoo Finance • 16 days ago

Stephen K. Brannan, MD, and John D. Young Appointed to Slate Medicines Board of Directors

By Karen Roman Slate Medicines, Inc. said Stephen K. Brannan, MD, and John D. Young were appointed to the company's Board of Directors. Dr. Brannan has over 25 years of clinical development experience in central nervous system disorders... Full story

Yahoo Finance • 16 days ago

Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

Asian equities traded in the US as American depositary receipts were tracking higher Tuesday morning PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 17 days ago

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16 VERDICT is the first trial to provide macro... Full story

Yahoo Finance • 20 days ago

Alkermes reinstated Buy at Truist on narcolepsy opportunity

[New York City Wall Street] rabbit75_ist Truist Securities on Friday reinstated its coverage of Alkermes (ALKS [https://seekingalpha.com/symbol/ALKS]) with a Buy recommendation and a $55 per share target, citing the potential of its lead... Full story

Yahoo Finance • 21 days ago

Asian Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

Asian equities traded in the US as American depositary receipts were tracking lower Thursday morning PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 28 days ago

eClinical Solutions Turns Clinical Data Intelligence Into Action at ENGAGE 2026

Leading industry experts will come together for multi-day conference to discuss how advancements in AI-driven automation, agentic AI, and data analytics will accelerate clinical trials BOSTON, October 08, 2026--(BUSINESS WIRE)--eClinical... Full story

Yahoo Finance • 30 days ago

Biopharma's Leapfrog Moment: The Launch of the Digital CMC Consortium

Uniting industry leaders to build the digital standards and infrastructure needed for the future of drug development DOVER, Del., Oct. 6, 2026 /PRNewswire/ -- The Digital CMC Consortium today launched as a new industry collaboration uniti... Full story

Yahoo Finance • last month

Will Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline Narrative

Takeda Pharmaceutical recently reported Phase 3 data showing that its investigational oral TYK2 inhibitor, zasocitinib (TAK-279), achieved statistically superior complete skin clearance versus deucravacitinib and outperformed apremilast in... Full story

Yahoo Finance • last month

Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading

Asian equities traded in the US as American depositary receipts were tracking modestly higher Wednes PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

Ginkgo generates antibody data at scale and trains models for drug manufacturability and developability. Apheris' federated infrastructure enables participating pharmaceutical companies to use those models and further fine-tune them on the... Full story

Yahoo Finance • last month

Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development

Iambic Therapeutics, Inc., an AI drug discovery company backed by Nvidia Corp.(NASDAQ:NVDA) and the Qatar Investment Authority, filed for an initial public offering, according to an S-1 filing with the SEC on Monday. Plans to List on Nasd... Full story

Yahoo Finance • 2 months ago

Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?

Bristol Myers BMY recently announced positive two-year results from the late-stage POETYK PsA-2 study on Sotyktu (deucravacitinib), including its open-label extension (OLE). The two-year data provide additional support for Sotyktu's comme... Full story

Yahoo Finance • 2 months ago

Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?

Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on September 14 that the FDA accepted its New Drug Application for zasocitinib under priority review for adults with moderate-to-severe plaque psoriasis. The target action date fal... Full story

Yahoo Finance • 2 months ago

Hummingbird Bioscience Appoints Dr. James Garner as President

Hummingbird Bioscience Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscienc... Full story

Yahoo Finance • 2 months ago

Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Monday Trading

Asian equities traded in the US as American depositary receipts started the trading week heading sha PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing the stability of a diversified pharmaceutical giant against the high-growth, high-margin profile of a specialized biotechnology pioneer. Amge... Full story